ArriVent says Phase 3 FURVENT trial of firmonertinib misses primary PFS endpoint
AVBP•ArriVent said its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC missed its primary progression-free survival endpoint. Independent review showed no meaningful improvement versus chemotherapy, while secondary measures indicated clinical activity and an early signal that overall survival may favor firmonertinib as data mature.
1. Trial results
ArriVent said the Phase 3 FURVENT trial missed its main goal, with independent review showing no meaningful improvement in progression-free survival versus chemotherapy. Secondary measures indicated clinical activity, and an early signal suggested overall survival may favor firmonertinib as data mature. Safety matched prior studies, with no new issues flagged.
